

GENERAL INTRODUCTION
1. METABOLOMICS AS A SOURCE OF BIOMARKERS OF DISEASE	1
1.1 METABOLOMIC APPROACHES.....	3
1.2 THE METABOLOMIC WORKFLOW	3
1.3 ANALYTICAL PLATFORMS FOR METABOLOMICS	5
1.4 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY	7
1.4.1 NMR spectroscopy principles.....	8
1.4.2 ¹ H-NMR experiments	12
1.4.3 HRMAS NMR spectroscopy.....	13
1.5 STATISTICAL ANALYSIS.....	14
1.5.1 Multivariate analysis	15
2. ALZHEIMER'S DISEASE	20
2.1 ETIOLOGY OF THE DISEASE	21
2.2 THE COURSE OF ALZHEIMER'S DISEASE	23
2.3 DIAGNOSIS CRITERIA.....	24
2.4 THE NEED OF NEW BIOMARKERS. METABOLISM AND AD.....	26
3. PRIMARY OPEN ANGLE GLAUCOMA.....	28
3.1 ETIOLOGY OF THE DISEASE	28
3.2 CURRENT DIAGNOSIS.....	30
3.3 THE NEED OF NEW BIOMARKERS. METABOLISM AND POAG	31
4. ATHEROSCLEROSIS AND PLAQUE VULNERABILITY.....	32
4.1 ETIOLOGY OF THE DISEASE	34
4.2 PLAQUE VULNERABILITY	35

4.3 CURRENT DIAGNOSIS STRATEGIES.....	36
4.4 THE NEED FOR NEW BIOMARKERS. METABOLISM AND ATHEROSCLEROSIS.....	37
5. COVID-19 AND PULMONARY FIBROSIS.....	38
5.1 COVID-19 PNEUMONIA AND POST-COVID PULMONARY FIBROSIS.....	40
5.2 CURRENT DIAGNOSIS.....	40
5.3 THE NEED FOR NEW BIOMARKERS.....	41
6. BIBLIOGRAPHY.....	42
OBJECTIVES.....	53
CHAPTER 1 NON-INVASIVE BIOMARKERS FOR MILD COGNITIVE IMPAIRMENT AND	
ALZHEIMER'S DISEASE.....	57
1. ABSTRACT.....	63
2. INTRODUCTION.....	64
3. MATERIAL AND METHODS.....	68
3.1 PATIENT SELECTION.....	68
3.2 COGNITIVE ASSESSMENT.....	71
3.3 SAMPLE PREPARATION.....	71
3.4 NMR SPECTRA ACQUISITION AND PROCESSING.....	72
3.5 MULTIVARIATE STATISTICAL ANALYSIS.....	73
3.6 UNIVARIATE STATISTICAL ANALYSIS.....	74
3.7 ANALYSIS OF ALTERED METABOLIC PATHWAYS IN AD AND MCI.....	74
4. RESULTS AND DISCUSSION.....	75

4.1 METABOLIC PROFILE OF SERUM SAMPLES	75
4.2 MULTIVARIATE ANALYSIS OF THE SERUM METABOLOMIC PROFILES	77
4.3 MEAN COMPARISON OF METABOLITES	81
4.4 METABOLIC CHANGES BETWEEN MCI PATIENTS WITH DIFFERENT PROGRESSION RATES	83
5. CONCLUSIONS.....	88
6. BIBLIOGRAPHY.....	89
7. SUPPORTING INFORMATION	95
CHAPTER 2 HIGHLY SENSITIVE AND SPECIFIC APPROACH TO IDENTIFY METABOLITES AND PATHWAYS IN EARLY ALZHEIMER DISEASE	99
1.ABSTRACT.....	105
2.INTRODUCTION	106
3. MATERIALS AND METHODS	107
3.1 PARTICIPANT SELECTION AND SAMPLE COLLECTION	107
3.2 LIPID PEROXIDATION METABOLITES DETERMINATION BY MEANS OF UPLC-MS/MS	108
3.3 METABOLITES IDENTIFICATION BY MEANS OF NMR.....	109
3.4 MULTIVARIATE STATISTICAL ANALYSIS	110
3.5 UNIVARIATE STATISTICAL ANALYSIS.....	111
3.6 METABOLITE SET ENRICHMENT ANALYSIS.....	111
4. RESULTS.....	112
4.1 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE PARTICIPANTS	112
4.2 PLASMA METABOLOMIC PROFILES	113

4.3 PLASMA LIPID PEROXIDATION METABOLITES	116
4.4 INTEGRATION OF PLASMA METABOLOMIC PROFILES AND LIPID PEROXIDATION METABOLITES	119
4.5 IMPAIRED PATHWAYS IN EARLY AD.....	122
5. DISCUSSION	123
6. BIBLIOGRAPHY.....	125
 CHAPTER 3 TEAR METABOLOMICS FOR THE DIAGNOSIS OF PRIMARY OPEN-ANGLE	
GLAUCOMA.....	131
1. ABSTRACT.....	137
2. INTRODUCTION.....	138
3. MATERIALS AND METHODS.....	140
3.1 FOCUSED TOPIC AND STUDY CHARACTERISTICS.....	140
3.2 ELIGIBILITY REQUIREMENTS FOR THE STUDY PARTICIPANTS	140
3.3. SAMPLE COLLECTION.	143
3.4 SAMPLE PREPARATION FOR ¹ H-NMR SPECTROSCOPY STUDY	144
3.5 NMR SPECTRA ACQUISITION AND PROCESSING.....	145
3.6 STATISTICAL ANALYSIS	146
3.6.1. <i>General Statistical Proceedings</i>	146
3.6.2 <i>Analysis of altered metabolic pathways</i>	147
4. RESULTS.....	148
4.1 PATIENT CHARACTERISTICS.....	148
4.2 SYSTEMIC AND OPHTHALMOLOGIC CLINICAL CHARACTERISTICS.....	148
4.3 ¹ H-NMR SPECTROSCOPY STUDY.....	150
4.3.1. <i>¹H-POGNMR profile of tears obtained from the study participants</i>	150

4.3.2 *Multivariate data analysis of the tear metabolomic profiles* 153

4.3.3 *Mean comparison of metabolites included in the discriminative model* 155

4.3.4 *Metabolic Pathways Analysis* 157

.....158

5. DISCUSSION159

6. BIBLIOGRAPHY164

7. SUPPORTING INFORMATION170

**CHAPTER 4 | METABOLOMIC STUDY FOR THE IDENTIFICATION OF SYMPTOMATIC CAROTID
PLAQUE BIOMARKERS**173

1. ABSTRACT179

2. INTRODUCTION.....180

3. MATERIALS AND METHODS182

3.1 PATIENTS SELECTION 182

3.2 SAMPLE COLLECTION 183

3.3 SAMPLE PREPARATION 183

3.4 NMR SPECTRA ACQUISITION AND PROCESSING 184

3.5 MULTIVARIATE STATISTICAL ANALYSIS 185

3.6 UNIVARIATE STATISTICAL ANALYSIS..... 186

3.7 METABOLITE SET ENRICHMENT ANALYSIS..... 186

4. RESULTS AND DISCUSSION186

4.1 METABOLIC PROFILING OF ATHEROSCLEROTIC PLAQUE TISSUES AND SERUM SAMPLES 187

4.2 IDENTIFICATION OF POTENTIAL BIOMARKERS OF VULNERABILITY IN PLAQUE AND SERUM 189

4.3 METABOLIC PATHWAYS INVOLVED IN PLAQUE VULNERABILITY..... 194

5. CONCLUSIONS.....	196
6. BIBLIOGRAPHY.....	197
CHAPTER 5 EARLY BIOMARKERS OF FIBROSIS IN COVID-19 PATIENTS ONE YEAR AFTER HOSPITAL DISCHARGE.....	203
1. ABSTRACT.....	209
2. INTRODUCTION.....	209
3. MATERIAL AND METHODS.....	211
3.1 STUDY DESIGN.....	211
3.2 PATIENT SELECTION.....	212
3.3 HOSPITAL PROCEDURES.....	213
3.4 SAMPLE PREPARATION.....	215
3.5 NMR SPECTRA ACQUISITION AND PROCESSING.....	215
3.6 MULTIVARIATE STATISTICAL ANALYSIS.....	216
3.7 UNIVARIATE STATISTICAL ANALYSIS.....	217
3.8 METABOLIC PATHWAYS ANALYSIS.....	217
4. RESULTS.....	218
4.1 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE PARTICIPANTS.....	218
4.2 METABOLIC PROFILING OF SERUM SAMPLES.....	219
4.3 STATISTICAL ANALYSIS OF SERUM SAMPLES.....	221
4.4 METABOLIC PATHWAYS ANALYSIS.....	224
5. DISCUSSION.....	225

6. BIBLIOGRAPHY.....	227
GENERAL DISCUSSION.....	233
CONCLUSION	239